CARDIOVASCULAR PATHOLOGY IN CHILDREN WITH TYPE I MUCOPOLYSACCHARIDOSIS

The article present current published data on the incidence rate, pathogenesis, clinical manifestations, diagnosis and treatment of
life-threatening conditions of the cardiovascular system at type I mucopolysaccharidosis (MPS). Mucopolysaccharidosis is a rare
genetically determined disease with chronic progressive course and wide range of clinical manifestations. Specific relevance of the
disease is justified by its severe incapacitating potential, development of a large number of complications of various organs and systems (up to failure), difficulty diagnosing and high risk of fatal outcomes as early as in childhood. Prevalence and severity of cardiovascular disorders in such patients is very high. Currently, there are two methods of treating MPS patients based on pathophysiology of this disease: transplantation of hemopoietic stem cells, which is used only in certain patients, and enzyme-replacement therapy. Early diagnosis and timely launched treatment help to improve condition of patients, attenuate the disease course, including termination of progression of cardiac disorders.

1. Muenzer J., Wraith J.E., Clarke L.A. International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009; 123 (1): 19–29.

2. Hurler G. Über einen Typ multipler Abartungen, vorwiegend am Skelettsystem. Zeitschrift für Kinderheilkunde. 1919; 24: 220.

3. Beesley C.E., Meaney C.A., Greenland G., Adams V., Vellodi A., Young E.P., Winchester B.G. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet. 2001; 109: 503–511.

4. Atlas redkikh boleznei. pod red. A.A. Baranova, L.S. Namazovoi-Baranovoi [Atlas of Rare Diseases. Edited by A.A. Baranov, L.S. Namazova-Baranova]. Moscow, Pediatr"", 2013. 304 p.

5. Stenson P.D., Ball E.V., Mort M., Phillips A.D., Shiel J.A., Thomas N.S., Abeysinghe S., Krawczak M., Cooper D.N. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat. 2003; 21: 577–581.

6. Moore D., Connock M.J., Lavery Ch. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler–Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008; 3: 24.

7. Lin S.-P., Lin H.-Y., Wang T.-J. A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan. Orphanet Journal of Rare Diseases. 2013; 8 (1): 147.

8. Pinto R., Caseiro C., Lemos M. еt al. Prevalence of lysosomal storage diseases in Portugal. European Journal of Human Genetics. 2004; 12: 87–92.

9. Baehner F.I., Schmiedeskamp C., Kampmann C., Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. Inherit Metab Dis. 2005; 28 (6): 1011–1017.

10. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. Scriver CRBeaudet ALSly WS Vale DedsThe Metabolic and Molecular Basis of Inherited Disease. 38th Berkshire. England McGraw-Hill Co Inc. 2001. Р. 3421–3452.

11. Neufeld E.F., Muenzer J. In The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw-Hill. 2001. Р. 3421.

12. McKusick V.A. The nosology of the mucopolysaccharidoses. Am J Med. 1969; 47: 730–747.

13. McKusick V.A., Kaplan D., Wise D. et al. The genetic mucopolysaccharidoses. Medicine (Baltimore). 1965; 44: 445–483.

14. Chen M.R., Lin S.P., Hwang H.K., Yu C.H. Cardiovascular changes in mucopolysaccharidoses in Taiwan. Acta Cardiol. 2005; 60: 51–53.

15. Donaldson M.D.C., Pennock C.A. et al. Hurler syndrome with cardiomyopathy in infancy. J Pediatr. 1989; 114: 430.

16. Dangel J.H. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders ― clinical and echocardiographic findings in 64 patients. Eur J Pediatr. 1998; 157: 534–538.

17. Fesslová V., Corti P., Sersale G. et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young. 2009; 19: 170–178.

18. Wippermann C.F., Beck M., Schranz D., Huth R., Michel-Behnke I., Jüngst B.K. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr. 1995; 154: 98–101.

19. Hunter C. A rare disease in two brothers. Proc R Soc Med. 1917; 10 (Sect Study Dis Child): 104–116.

20. Grande-Allen K.J., Griffin B.P., Ratliff N.B., Cosgrove D.M., Vesely I. Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations. J Am Coll Cardiol. 2003; 42: 271–277.

21. Latif N., Sarathchandra P., Taylor P.M., Antoniw J., Yacoub M.H. Localization and pattern of expression of extracellular matrix components in human heart valves. J Heart Valve Dis. 2005; 14: 218–227.

22. Braunlin E.A., Berry J.M., Whitley C.B. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol. 2006; 98: 416–418.

23. Simonaro C.M. Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation. J Pediatr Rehabil Med. 2010; 3: 85–88.

24. Butman S.M., Karl L., Copelands J.G. Combined aortic and mitral valve replacement in an adult with Scheie’s disease. Chest. 1989; 96: 209.

25. Chen Jing. Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Shanghai 200127, Major Concepts: Pharmacology; Metabolism; Medical Genetics (Allied Medical Sciences). Peoples R China ISSN: 1003–9406.

26. Krivit W., Pierpont M.E., Ayaz K. et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med. 1984; 311: 1606–1611.

27. Thomas J.A., Beck M., Clarke J.T.R., Cox G.F. Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis. 1002; 33: 421–427.

28. Renteria V.G., Ferrans V.J., Roberts W.C. The heart in the Hurler syndrome. Gross, histologic and ultrastructural observations in five necropsy cases. Am J Cardiol. 1976; 38: 487–501.

29. Braunlin E.A., Rose A.G., Hopwood J.J., Candel R.D., Krivit W. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2001; 88: 1075–1077.

30. Wraith J.E. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child. 1995; 72: 263–267.

31. Hinek A., Wilson S.E. Impaired elastogenesis in Hurler disease. Dermatan sulfate accumulation linked to deficiency in elastinbinding protein and elastic fiber assembly. Am J Pathol. 2000; 156: 925–938.

32. Dilber E., Celiker A., Karagöz T., Kalkanoglu H.S. Permanent transfemoral pacemaker implantation in a child with Maroteaux Lamy syndrome. Pacing Clin Electrophysiol. 2002; 25: 1784–1785.

33. Fleming D.R., Hensee-Downey P.J., Ciocci G. et al. The use of partially HLA-mismatched donors for allogenic transplantation in patients with mucopolysaccharidosis 1. Pediatric Transplantation. 1998; 2 (4): 299–304.

34. Orchard P.J., Blazar B.R., Wagner J., Charnas L., Krivit W., Tolar J. Hematopoietic cell therapy for metabolic disease. J Pediatr. 2007; 151: 340–346.

35. Braunlin E.A., Stauffer N.R., Peters C.H. et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2003; 92: 882–886.

36. Malm G., Gustafsson B., Berglund G. et al. Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplant ation (HSCT). Acta Paediatr. 2008; 97: 1108–1112.

37. Okuyama T., Tanaka A., Suzuki Y. et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010; 99: 18–25.

38. Gabrielli O., Clarke L.A., Bruni S., Coppa G.V. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2010; 125: e183–e187.